Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma
Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting ar...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/24/13635 |
| _version_ | 1797503752808169472 |
|---|---|
| author | Robert Cornelison Laine Marrah Drew Horter Sarah Lynch Hui Li |
| author_facet | Robert Cornelison Laine Marrah Drew Horter Sarah Lynch Hui Li |
| author_sort | Robert Cornelison |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope. |
| first_indexed | 2024-03-10T03:54:50Z |
| format | Article |
| id | doaj.art-9f2d4709766b4d9ca1990a00fe566515 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T03:54:50Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9f2d4709766b4d9ca1990a00fe5665152023-11-23T08:49:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-12-0122241363510.3390/ijms222413635Targeting AVIL, a New Cytoskeleton Regulator in GlioblastomaRobert Cornelison0Laine Marrah1Drew Horter2Sarah Lynch3Hui Li4Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USADepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USADepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USADepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USADepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USAGlioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope.https://www.mdpi.com/1422-0067/22/24/13635glioblastomaAVILFOXM1LIN28Bactingelsolin |
| spellingShingle | Robert Cornelison Laine Marrah Drew Horter Sarah Lynch Hui Li Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma International Journal of Molecular Sciences glioblastoma AVIL FOXM1 LIN28B actin gelsolin |
| title | Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma |
| title_full | Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma |
| title_fullStr | Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma |
| title_full_unstemmed | Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma |
| title_short | Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma |
| title_sort | targeting avil a new cytoskeleton regulator in glioblastoma |
| topic | glioblastoma AVIL FOXM1 LIN28B actin gelsolin |
| url | https://www.mdpi.com/1422-0067/22/24/13635 |
| work_keys_str_mv | AT robertcornelison targetingavilanewcytoskeletonregulatoringlioblastoma AT lainemarrah targetingavilanewcytoskeletonregulatoringlioblastoma AT drewhorter targetingavilanewcytoskeletonregulatoringlioblastoma AT sarahlynch targetingavilanewcytoskeletonregulatoringlioblastoma AT huili targetingavilanewcytoskeletonregulatoringlioblastoma |